CD74 and non-small cell lung carcinoma: Next-generation TKIs have shown promise in addressing crizotinib-resistant NSCLC, including repotrectinib for the G2032R/D2033N fusion mutation, orlatinib and taletrectinib for the G2032R fusion mutation, and cabozantinib and brigatinib for the CD74 fusion mutation.